Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox)
Intestinal Microbiome Profiles in Women With Gynecological Tumors and Pelvic Toxicity Secondary to Radiotherapy and Chemotherapy: Comparison With Controls and Effect of Rectal Ozone Treatment.
- Pelvic Toxicity
- Radiation Toxicity
- Chemotherapy Toxicity
- Gynecological Tumors
- Radiation Proctitis
- Radiation Cystitis
- Vaginal Mucositis
- Vulvar Mucositis
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Bernardino Clavo, MD, PhD
- Enrolment target
- 38
- Started
- 15 January 2026
- Main results due
- 15 January 2028
- Study sites
- 2
- Registry updated
- 23 September 2026
Can you take part?
- Aged 18 years and over.
- Women only.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria for all patients (Cases and Controls): 1. Adult women (\>=18 years). 2. Diagnosed with gynecological tumors (any location and stage). 3. Previously treated with radiotherapy and/or chemotherapy. 4. Must accept and sign the specific informed consent for this study. Additional Inclusion Criteria for inclusion in the TPIRQT Group (Cases): 5. Must present chronic TPIRQT with \>= 3 months of duration after habitual symptomatic treatment. 6. Must have a toxicity Grade of 2 (moderate symptoms, limiting instrumental ADL) or higher, according to the CTCAE v.5.0 scale. Exclusion Criteria for all patients (Cases and Controls): 1. Not meeting all inclusion criteria. 2. Presence of active inflammatory bowel disease (e.g., Crohn's Disease, Ulcerative Colitis) or a history of major gastrointestinal resection (excluding appendectomy) that could significantly alter gut anatomy and microbiota. 3. Any uncontrolled intercurrent illness or psychiatric condition that, in the investigator's opinion, would limit compliance with study requirements or interfere with the interpretation of results. 4. Unwillingness or inability to provide written informed consent for study participation.
What this study is about
In the sponsor’s own words, from the registry.
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
Study sites(2)
Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC)
Las Palmas de Gran Canaria, Las Palmas, Spain
Recruiting
Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias - Universidad de La Laguna
San Cristóbal de La Laguna, Tenerife, Spain
Recruiting
Showing 2 of 2 sites. 2 of the 2 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07259681. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me